These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
318 related articles for article (PubMed ID: 32358952)
21. A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19. Kim AHJ; Sparks JA; Liew JW; Putman MS; Berenbaum F; Duarte-García A; Graef ER; Korsten P; Sattui SE; Sirotich E; Ugarte-Gil MF; Webb K; Grainger R; Ann Intern Med; 2020 Jun; 172(12):819-821. PubMed ID: 32227189 [TBL] [Abstract][Full Text] [Related]
22. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. Juurlink DN CMAJ; 2020 Apr; 192(17):E450-E453. PubMed ID: 32269021 [No Abstract] [Full Text] [Related]
23. Rheumotologitsts' view on the use of hydroxychloroquine to treat COVID-19. Sun X; Ni Y; Zhang M Emerg Microbes Infect; 2020 Dec; 9(1):830-832. PubMed ID: 32338155 [TBL] [Abstract][Full Text] [Related]
24. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Andreani J; Le Bideau M; Duflot I; Jardot P; Rolland C; Boxberger M; Wurtz N; Rolain JM; Colson P; La Scola B; Raoult D Microb Pathog; 2020 Aug; 145():104228. PubMed ID: 32344177 [TBL] [Abstract][Full Text] [Related]
25. All together to Fight COVID-19. Momtazmanesh S; Ochs HD; Uddin LQ; Perc M; Routes JM; Vieira DN; Al-Herz W; Baris S; Prando C; Rosivall L; Abdul Latiff AH; Ulrichs T; Roudenok V; Aldave Becerra JC; Salunke DB; Goudouris E; Condino-Neto A; Stashchak A; Kryvenko O; Stashchak M; Bondarenko A; Rezaei N Am J Trop Med Hyg; 2020 Jun; 102(6):1181-1183. PubMed ID: 32323644 [TBL] [Abstract][Full Text] [Related]
26. QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19. Wu TC; Sacilotto L; Darrieux FCDC; Pisani CF; Melo SL; Hachul DT; Scanavacca M Arq Bras Cardiol; 2020 Jun; 114(6):1061-1066. PubMed ID: 32638906 [No Abstract] [Full Text] [Related]
27. Repurposing antimalarials and other drugs for COVID-19. Schlagenhauf P; Grobusch MP; Maier JD; Gautret P Travel Med Infect Dis; 2020; 34():101658. PubMed ID: 32247925 [No Abstract] [Full Text] [Related]
28. COVID-19: Shining the Light on Africa. Rosenthal PJ; Breman JG; Djimde AA; John CC; Kamya MR; Leke RGF; Moeti MR; Nkengasong J; Bausch DG Am J Trop Med Hyg; 2020 Jun; 102(6):1145-1148. PubMed ID: 32372749 [No Abstract] [Full Text] [Related]
29. Drug targets for COVID-19 therapeutics: Ongoing global efforts. Saxena A J Biosci; 2020; 45(1):. PubMed ID: 32661214 [TBL] [Abstract][Full Text] [Related]
30. Lessons from the Italian COVID-19 frontline. Bellan M; Sainaghi PP; Gavelli F; Patrucco F; Avanzi GC; Pirisi M; Castello LM Minerva Med; 2020 Aug; 111(4):303-305. PubMed ID: 33032392 [No Abstract] [Full Text] [Related]
31. News Feature: To counter the pandemic, clinicians bank on repurposed drugs. Madhusoodanan J Proc Natl Acad Sci U S A; 2020 May; 117(20):10616-10620. PubMed ID: 32350142 [No Abstract] [Full Text] [Related]
32. Hydroxychloroquine in Covid-19: Does the end justify the means? Yakoub-Agha I Curr Res Transl Med; 2020 Aug; 68(3):81-82. PubMed ID: 32340837 [No Abstract] [Full Text] [Related]
33. Possible Consequences of a Shortage of Hydroxychloroquine for Patients with Systemic Lupus Erythematosus amid the COVID-19 Pandemic. Peschken CA J Rheumatol; 2020 Jun; 47(6):787-790. PubMed ID: 32269064 [No Abstract] [Full Text] [Related]
35. The impact of hydroxychloroquine shortages on patients with dermatological conditions during COVID-19 pandemic. Shah M; Sachdeva M; Dodiuk-Gad RP Dermatol Ther; 2020 Jul; 33(4):e13524. PubMed ID: 32383251 [No Abstract] [Full Text] [Related]
36. COVID-19, severe asthma, and biologics. García-Moguel I; Díaz Campos R; Alonso Charterina S; Fernández Rodríguez C; Fernández Crespo J Ann Allergy Asthma Immunol; 2020 Sep; 125(3):357-359.e1. PubMed ID: 32553608 [No Abstract] [Full Text] [Related]
37. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Furtado RHM; Berwanger O; Fonseca HA; Corrêa TD; Ferraz LR; Lapa MG; Zampieri FG; Veiga VC; Azevedo LCP; Rosa RG; Lopes RD; Avezum A; Manoel ALO; Piza FMT; Martins PA; Lisboa TC; Pereira AJ; Olivato GB; Dantas VCS; Milan EP; Gebara OCE; Amazonas RB; Oliveira MB; Soares RVP; Moia DDF; Piano LPA; Castilho K; Momesso RGRAP; Schettino GPP; Rizzo LV; Neto AS; Machado FR; Cavalcanti AB; Lancet; 2020 Oct; 396(10256):959-967. PubMed ID: 32896292 [TBL] [Abstract][Full Text] [Related]
38. Chloroquine and hydroxychloroquine in covid-19. Ferner RE; Aronson JK BMJ; 2020 Apr; 369():m1432. PubMed ID: 32269046 [No Abstract] [Full Text] [Related]
39. Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment? Patrì A; Fabbrocini G J Am Acad Dermatol; 2020 Jun; 82(6):e221. PubMed ID: 32283237 [No Abstract] [Full Text] [Related]
40. Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome. Okour M; Al-Kofahi M; Austin D J Pharmacokinet Pharmacodyn; 2020 Jun; 47(3):187-188. PubMed ID: 32405664 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]